GAMMA Investing LLC Has $611,000 Stock Holdings in Kiniksa Pharmaceuticals International, plc (NASDAQ:KNSA)

GAMMA Investing LLC grew its stake in Kiniksa Pharmaceuticals International, plc (NASDAQ:KNSA - Free Report) by 4,003.9% in the 1st quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 27,496 shares of the company's stock after acquiring an additional 26,826 shares during the period. GAMMA Investing LLC's holdings in Kiniksa Pharmaceuticals International were worth $611,000 at the end of the most recent quarter.

A number of other hedge funds and other institutional investors have also modified their holdings of KNSA. Wellington Management Group LLP boosted its position in Kiniksa Pharmaceuticals International by 46.3% during the fourth quarter. Wellington Management Group LLP now owns 69,813 shares of the company's stock valued at $1,381,000 after purchasing an additional 22,096 shares during the last quarter. Jefferies Financial Group Inc. raised its stake in shares of Kiniksa Pharmaceuticals International by 39.5% during the 4th quarter. Jefferies Financial Group Inc. now owns 112,400 shares of the company's stock worth $2,223,000 after purchasing an additional 31,800 shares in the last quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC boosted its holdings in shares of Kiniksa Pharmaceuticals International by 28.2% in the 4th quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 56,691 shares of the company's stock valued at $1,121,000 after buying an additional 12,462 shares during the last quarter. Squarepoint Ops LLC acquired a new stake in shares of Kiniksa Pharmaceuticals International in the 4th quarter valued at approximately $530,000. Finally, State of Wyoming bought a new position in shares of Kiniksa Pharmaceuticals International in the fourth quarter valued at $293,000. Institutional investors and hedge funds own 53.95% of the company's stock.

Kiniksa Pharmaceuticals International Price Performance

KNSA stock traded down $0.02 during midday trading on Thursday, reaching $27.93. 487,811 shares of the company were exchanged, compared to its average volume of 517,873. Kiniksa Pharmaceuticals International, plc has a one year low of $17.38 and a one year high of $30.69. The firm has a market capitalization of $2.04 billion, a price-to-earnings ratio of -111.72 and a beta of 0.06. The business has a 50-day moving average price of $25.63 and a two-hundred day moving average price of $22.29.

Kiniksa Pharmaceuticals International (NASDAQ:KNSA - Get Free Report) last posted its earnings results on Tuesday, April 29th. The company reported $0.11 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $0.02 by $0.09. Kiniksa Pharmaceuticals International had a negative net margin of 3.52% and a negative return on equity of 3.83%. The company had revenue of $137.79 million during the quarter, compared to analysts' expectations of $128.35 million. During the same quarter last year, the company posted ($0.25) EPS. Kiniksa Pharmaceuticals International's quarterly revenue was up 72.5% compared to the same quarter last year. As a group, analysts anticipate that Kiniksa Pharmaceuticals International, plc will post -0.55 earnings per share for the current fiscal year.

Insiders Place Their Bets

In other Kiniksa Pharmaceuticals International news, COO Eben Tessari sold 12,000 shares of the business's stock in a transaction dated Monday, April 14th. The shares were sold at an average price of $20.48, for a total value of $245,760.00. Following the completion of the sale, the chief operating officer now owns 77,363 shares of the company's stock, valued at $1,584,394.24. The trade was a 13.43% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available at the SEC website. Also, CEO Sanj K. Patel sold 2,872 shares of the stock in a transaction that occurred on Tuesday, May 13th. The stock was sold at an average price of $27.03, for a total transaction of $77,630.16. Following the transaction, the chief executive officer now owns 96,674 shares in the company, valued at approximately $2,613,098.22. The trade was a 2.89% decrease in their position. The disclosure for this sale can be found here. Insiders sold 440,863 shares of company stock worth $12,101,029 over the last three months. Insiders own 53.48% of the company's stock.

Wall Street Analysts Forecast Growth

Several research firms have issued reports on KNSA. Citigroup initiated coverage on shares of Kiniksa Pharmaceuticals International in a research report on Thursday, March 13th. They set a "buy" rating and a $40.00 price target on the stock. Jefferies Financial Group boosted their price objective on shares of Kiniksa Pharmaceuticals International from $40.00 to $45.00 and gave the stock a "buy" rating in a research note on Tuesday, April 29th. Wall Street Zen upgraded shares of Kiniksa Pharmaceuticals International from a "hold" rating to a "buy" rating in a research note on Saturday, June 14th. Finally, Wedbush reiterated an "outperform" rating and set a $34.00 price target on shares of Kiniksa Pharmaceuticals International in a report on Wednesday, April 16th. Six research analysts have rated the stock with a buy rating, According to MarketBeat.com, the stock presently has a consensus rating of "Buy" and a consensus price target of $38.80.

Kiniksa Pharmaceuticals International Company Profile

Kiniksa Pharmaceuticals, Ltd., a biopharmaceutical company, focuses on discovering, acquiring, developing, and commercializing therapeutic medicines for patients suffering from debilitating diseases with significant unmet medical needs worldwide. Its product candidates include ARCALYST, an interleukin-1alpha and interleukin-1beta, for the treatment of recurrent pericarditis, which is an inflammatory cardiovascular disease; Mavrilimumab, a monoclonal antibody inhibitor that completed Phase II clinical trials for the treatment of giant cell arteritis; Vixarelimab, a monoclonal antibody, that is in Phase 2b clinical trial for the treatment of prurigo nodularis, a chronic inflammatory skin condition; and KPL-404, a monoclonal antibody inhibitor of the CD40- CD154 interaction, a T-cell co-stimulatory signal critical for B-cell maturation, immunoglobulin class switching, and type 1 immune response.